BIIB:BCBA
Biogen Inc Cedear
ARS 25,000.00
arrow_downward
-3.77%(-980.00) 1D
Sep 9, 5:00:00 PM GMT-3 · ARS
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB...
Open
ARS 25,500.00
High
ARS 26,180.00
Low
ARS 25,000.00
Mkt. cap
31.14B
Avg. vol.
893.00
Volume
1.77K
52-wk high
ARS 27,600.00
52-wk low
ARS 14,590.00
Shares outstanding
147.75M
No. of employees
8K
Open
ARS 25,500.00
High
ARS 26,180.00
Low
ARS 25,000.00
Mkt. cap
31.14B
Avg. vol.
893.00
Volume
1.77K
52-wk high
ARS 27,600.00
52-wk low
ARS 14,590.00
Shares outstanding
147.75M
No. of employees
8K
News stories
From web sources and news partners
CNBC
·
6 hours ago
Biogen CEO: We are at that inflection point where we are on a path to sustainable revenue growth
Investing.com
·
7 hours ago
Biogen at Wells Fargo healthcare conference: growth bets widen
Simply Wall Street
·
17 hours ago
Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing
GuruFocus
·
23 hours ago
Biogen Inc (BIIB) Shares Fall 3.8% -- What GF Score of 73 Tells Investors
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc Cedear
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com